FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger ...
Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next ...
Personalis is a small-cap stock specializing in cancer genomics, with an advanced cancer diagnostics platform. The company reported significant losses in Q2 earnings but maintains a robust financial ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Personalis () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools ...
Personalis said clinical testing surged to 6,183 tests in Q4 (up 41% sequential, 329% YoY) and >16,000 tests in 2025, and set 2026 clinical volume guidance of 43,000–45,000 tests as it scales adoption ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced the issuance of a key US Patent related to its industry-leading minimal ...
Hosted on MSN
Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth
CEO Christopher Hall reported Q1 2025 revenue of $20.6 million, marking a strong start to the year. He highlighted significant progress in their "Win-in-MRD" strategy, driven by demand for the company ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public offering of $150.0 million of its ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option added to its ultrasensitive NeXT ...
Tachibana provided third quarter 2025 guidance of total company revenue in the range of $12 million to $14 million and pharma test/services revenue in the range of $11 million to $13 million.
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results